+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 20 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of oral AP1189 combined with methotrexate in adults with early rheumatoid arthritis who have not previously been treated with disease-modifying anti-rheumatic drugs DMARDs. This phase II, randomized, double-blind, placebo-controlled study aims to understand how different doses of AP1189 40, 70, or 100 mg impact disease activity and inflammation over 12 weeks in participants with active early rheumatoid arthritis. Participants will be randomly assigned to one of four groups, each receiving daily oral treatment for 12 weeks AP1189 at 40 mg, 70 mg, or 100 mg doses alongside methotrexate, or a placebo alongside methotrexate. The study compares the effects of these treatments on rheumatoid arthritis symptoms and inflammation to determine the best dose of AP1189 when combined with methotrexate. During the study, participants will attend scheduled visits for assessments including joint evaluations, blood tests for inflammation markers such as C-reactive protein CRP, and other safety monitoring. Researchers will measure changes in the Disease Activity Score 28 DAS28-CRP at 12 weeks to evaluate treatment impact. Participants will be monitored closely for safety and tolerability throughout the trial period, which lasts about 12 weeks.

Age: 18Years +All GendersPhase 2
11 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of abrocitinib oral suspension, with or without topical medications, in children aged 2 years and older who have moderate-to-severe atopic dermatitis. This Phase 3 open-label study includes two groups children who previously completed abrocitinib studies and those who have never participated in such studies. The study aims to better understand the treatments impact over an extended period. Participants will receive abrocitinib oral suspension throughout the study, which may last up to 24 months or until the medicine becomes commercially available, whichever happens first. The study will enroll up to 500 children globally, split between those continuing from previous trials and new participants aged 6 to under 12 years. All children will receive the same study treatment during this period. Throughout the study, participants will be closely monitored with regular assessments of safety, including treatment-related side effects and laboratory tests. Researchers will also evaluate skin condition improvements using various scales and indexes, itch intensity, quality of life measures, and the need for additional topical treatments. This comprehensive follow-up will last up to two years to track long-term effects and safety outcomes.

Age: 2Years - 11YearsAll GendersPhase 3
39 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
P

Actively Recruiting

Researchers are evaluating momelotinib in adults with low-risk myelodysplastic syndromes LR-MDS who have anemia requiring red blood cell transfusions. The study aims to find out if momelotinib is safe and effective by testing different doses and observing how the body processes the drug. This is a Phase 2, randomized, open-label trial sponsored by GlaxoSmithKline focusing on patients with specific risk classifications of MDS and transfusion needs. Participants will receive momelotinib at one of two dose levels to determine the optimal dose. The study involves monitoring drug levels in the blood and assessing changes in red blood cell transfusion requirements. The treatment period lasts up to 24 weeks for primary outcomes, with extended safety and response monitoring continuing for up to approximately 133 weeks. Throughout the trial, participants will have regular evaluations including blood tests, assessments of anemia improvement, and monitoring for any side effects or adverse events. The main outcomes measured include the percentage of participants achieving transfusion independence for at least 12 weeks and safety events related to treatment. Participants will be followed for up to about 2.5 years to evaluate long-term effects and drug processing in the body.

Age: 18Years +All GendersPhase 2
39 locations
P

Actively Recruiting

Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.

Age: 18Years +All GendersPhase 3
103 locations
I

Actively Recruiting

Researchers are studying abrocitinib to see if it improves eczema symptoms and is safe for children aged 6 to less than 12 years who have moderate-to-severe eczema. The study is a phase 3, randomized, double-blind, placebo-controlled trial that compares abrocitinib with a placebo. Participants will be randomly assigned to receive either the test medicine or placebo for 16 weeks, with the entire study lasting about 24 weeks. Participants will receive abrocitinib or placebo as a liquid oral suspension. They will use an electronic diary, similar to a cell phone, to record questionnaire responses and receive daily reminders to take the medication and complete questionnaires. They will also wear a wrist device resembling a childrens watch to monitor scratching caused by their eczema. The study involves regular clinic visits, laboratory tests, physical exams, and vital sign monitoring to assess health and treatment effects. During the study, researchers will assess eczema severity using validated scales such as the Investigators Global Assessment and the Eczema Area and Severity Index at week 12. They will also monitor itch severity and improvement through a numerical rating scale at weeks 2 and 12. Health checks including height, weight, temperature, blood pressure, and heart rate will be performed. Participants will have scheduled visits and phone calls with study staff to track progress and safety throughout the study period.

Age: 6Years - 11YearsAll GendersPhase 3
47 locations
R

Actively Recruiting

Researchers are evaluating IMVT-1402, a drug being studied for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug treatment. This Phase 2b, randomized, double-blind, placebo-controlled study aims to assess the drugs efficacy, safety, and tolerability in a global, multi-center setting. Participants are assigned to receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study compares these groups to see how well IMVT-1402 helps participants become euthyroid normal thyroid function and stop antithyroid drugs. The two doses are given over the same 26-week period, with monitoring at several time points. During the trial, participants will undergo regular evaluations including thyroid hormone measurements such as triiodothyronine T3 and free thyroxine FT4. Researchers will measure how many participants achieve normal thyroid hormone levels and are off antithyroid drugs by Week 26. Safety and tolerability are also monitored throughout. The main outcome is the percentage of participants who are euthyroid and off antithyroid drugs at Week 26, with follow-up assessments planned for this duration.

Age: 18Years - 75YearsAll GendersPhase 2
163 locations
E

Actively Recruiting

Researchers are evaluating how well elritercept works to improve anemia in adults with myelofibrosis MF who are already taking ruxolitinib. The study compares elritercept to a placebo and aims to learn if elritercept reduces tiredness, improves symptoms related to MF, helps participants be more active, and impacts the bone marrow and spleen. The safety of elritercept is also being assessed over a long period. This is a Phase 3, double-blind, randomized trial sponsored by Takeda. Participants will receive either elritercept or a matching placebo as a subcutaneous injection every 4 weeks for approximately 36 weeks during the double-blinded treatment period. Elritercept starts at a dose of 3.75 mgkg, with a possible increase to 5.0 mgkg from the third cycle based on response and safety. After this period, those on placebo may switch to elritercept during an extended open-label phase where dosing adjustments are also possible. During the study, participants will be monitored regularly with assessments including blood transfusion independence, fatigue levels, symptom scores, spleen size by imaging, and development of antibodies to the study drug. Researchers will track safety and overall survival for up to seven years. Participants can expect visits every 4 weeks during treatment, and the study includes long-term follow-up to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 3
195 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations

1-10 of 20

1